sc0023

SC0023 is a proprietary therapeutic aerosol composed of alkaline hypertonic divalent salts (HDS), specifically magnesium-chloride, which are endogenous to human airways[3][5][7]. It is designed to rehydrate and normalize the ionic environment of the upper airways, thereby deactivating mechano-sensitive ion channels implicated in chronic cough hypersensitivity[1][3][5]. SC0023 is being developed as a potential first-line treatment for refractory chronic cough (RCC), a condition with limited effective therapies, affecting about 10% of adults globally[1][3][5]. The drug is administered via inhalation, using a spray-mist device targeting the larynx[7]. Clinical trials indicate that daily treatment with SC0023 rapidly reduces cough frequency, with effects persisting for weeks after dosing, likely due to decompression and down-regulation of mechano-sensitive ion channels[1][2][3]. The therapy appears effective across a range of environmental conditions and cough severities[1][3]. SC0023 is based on over 20 years of scientific research into airway hydration and inflammation[3][5].

Other names

magnesium based alkaline hypertonic divalent salt aerosolmagnesium-chloride alkaline hypertonic divalent salt aerosol[7]HDS aerosol[3][5]